Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides - PubMed (original) (raw)

Comparative Study

. 1989 Nov 3;246(4930):668-70.

doi: 10.1126/science.2814489.

Affiliations

• PMID: 2814489
• DOI: 10.1126/science.2814489

Comparative Study

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

M D Howell et al. Science. 1989.

Erratum in

• Science 1990 Mar 9;247(4947):1167

Abstract

Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system mediated by CD4+ T cells reactive with myelin basic protein (MBP). Rats were rendered resistant to the induction of EAE by vaccination with synthetic peptides corresponding to idiotypic determinants of the beta chain VDJ region and J alpha regions of the T cell receptor (TCR) that are conserved among encephalitogenic T cells. These findings demonstrate the utility of TCR peptide vaccination for modulating the activity of autoreactive T cells and represent a general therapeutic approach for T cell-mediated pathogenesis.

PubMed Disclaimer

Similar articles

• Pretreatment with T cell receptor peptides using a conventional immunization protocol does not induce effective protection against autoimmune encephalomyelitis.
  Tanuma N, Abe S, Shin T, Kojima T, Ishihara Y, Arai Y, Toyoshima S, Matsumoto Y. Tanuma N, et al. Cell Immunol. 1996 Feb 25;168(1):85-90. doi: 10.1006/cimm.1996.0052. Cell Immunol. 1996. PMID: 8599843
• The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease.
  Kumar V, Sercarz EE. Kumar V, et al. J Exp Med. 1993 Sep 1;178(3):909-16. doi: 10.1084/jem.178.3.909. J Exp Med. 1993. PMID: 7688792 Free PMC article.
• Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis.
  Vandenbark AA, Hashim G, Offner H. Vandenbark AA, et al. Nature. 1989 Oct 12;341(6242):541-4. doi: 10.1038/341541a0. Nature. 1989. PMID: 2477708
• Myelin basic protein, MHC restriction molecules and T cell repertoire.
  Vandenbark AA, Hashim G, Offner H. Vandenbark AA, et al. Prog Clin Biol Res. 1990;336:93-108. Prog Clin Biol Res. 1990. PMID: 1691512 Review.
• The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease.
  Steinman L. Steinman L. Adv Immunol. 1991;49:357-79. doi: 10.1016/s0065-2776(08)60779-8. Adv Immunol. 1991. PMID: 1713016 Review. No abstract available.

Cited by

• Peptide-Based Vaccination Therapy for Rheumatic Diseases.
  Wang B, Chen S, Zheng Q, Liu Y, Shi G. Wang B, et al. J Immunol Res. 2020 Mar 18;2020:8060375. doi: 10.1155/2020/8060375. eCollection 2020. J Immunol Res. 2020. PMID: 32258176 Free PMC article. Review.
• Vaccination in Multiple Sclerosis: Friend or Foe?
  Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl UK. Zrzavy T, et al. Front Immunol. 2019 Aug 7;10:1883. doi: 10.3389/fimmu.2019.01883. eCollection 2019. Front Immunol. 2019. PMID: 31440255 Free PMC article. Review.
• Novel Molecular Leads for the Prevention of Damage and the Promotion of Repair in Neuroimmunological Disease.
  Kolahdouzan M, Futhey NC, Kieran NW, Healy LM. Kolahdouzan M, et al. Front Immunol. 2019 Jul 19;10:1657. doi: 10.3389/fimmu.2019.01657. eCollection 2019. Front Immunol. 2019. PMID: 31379852 Free PMC article. Review.
• Direct modulation of myelin-autoreactive CD4+ and CD8+ T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded major histocompatibility complexes, CD47 and multiple regulatory molecules.
  Pei W, Wan X, Shahzad KA, Zhang L, Song S, Jin X, Wang L, Zhao C, Shen C. Pei W, et al. Int J Nanomedicine. 2018 Jun 27;13:3731-3750. doi: 10.2147/IJN.S164500. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29983566 Free PMC article.
• Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.
  De Angelis F, Plantone D, Chataway J. De Angelis F, et al. CNS Drugs. 2018 Jun;32(6):499-526. doi: 10.1007/s40263-018-0538-0. CNS Drugs. 2018. PMID: 29968175 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal